Fig. 1From: Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancerImmune related mechanisms of action of HER2-targeted agents: trastuzumab (a), lapatinib (b), pertuzumab (c), T-DM1 (d)Back to article page